March 12, 2008 - Memory Pharmaceuticals Corp. (Nasdaq: MEMY) announced that it has realigned its operations, reallocated its resources and extended the preclinical research portion of its PDE10 collaboration with Amgen. The Company will focus its near-term and mid- term efforts on two partnered programs, its nicotinic alpha-7 receptor agonist collaboration with Roche and the PDE10 collaboration with Amgen, and two proprietary programs, its PDE4 inhibitor and 5-HT6 antagonist programs...
(...)
- 5-HT6 Antagonist Program. 5-HT6 antagonists are potential
treatments for Alzheimer's disease, schizophrenia, attention deficit
disorder and obesity. Memory Pharmaceuticals has generated a
portfolio of novel, potent and selective 5-HT6 antagonists and is
evaluating several lead compounds as potential development
candidates. The Company plans to advance the program into clinical
trials by the end of 2008...
Memory Pharmaceuticals' Press Release -
(...)
